IMNM January 2028 Options Begin Trading

Stock Options Channel highlights option strategies for Immunome Inc (IMNM, current price $20.16): selling the $20.00 put (bid $5.50) commits the seller to buy at $20 but nets a $14.50 cost basis and carries a 75% chance to expire worthless, implying a 27.50% return (13.60% annualized). A covered-call using the $22.00 strike (bid $6.50) sold against shares bought at $20.16 yields a potential 41.37% total return if called by Jan 2028, with a 28% chance to expire worthless and a 32.24% premium boost (15.95% annualized). Implied volatilities are elevated (puts 84%, calls 85%) versus a 12‑month trailing volatility of 78%; the publisher will track changing odds and option trading history on its contract pages.

Analysis

Market structure: Elevated implied vol (84–85% vs realized ~78%) and fat option premiums make IMNM favorable to premium sellers and market-makers collecting theta; short-dated and multi-year income strategies (sell puts/covered calls into Jan‑2028) win if no binary biotech event occurs. Buyers of upside (long equity) are diluted by potential covered‑call pressure if many write the $22 strike; the $20 put OTM by ~1% signals asymmetric retail demand for entry below current price. Cross-asset impact is minimal outside equities/options — a >40% biotech move could increase equity hedging flows and squeeze single‑name CDS/sector vols but won’t move rates or FX materially absent systemic news.

Risk assessment: Tail risks are classic biotech binaries — clinical readouts, regulatory rejection, or large secondary offerings could produce >50% drops within days; conversely positive data could spike price >100%, making covered-call sellers regretful. Immediate (days) risk: IV gap widens around catalysts; short term (weeks–months): theta decay benefits sellers but assignment risk grows as price approaches strikes; long term (to Jan‑2028): funding/dilution risk and program success drive fundamental value. Hidden dependencies include company cash runway and upcoming trial milestones—if cash <12 months runway, even neutral results could trigger dilutive raises.

Trade implications: Primary actionable trade is defined‑risk premium selling: sell IMNM Jan‑2028 $20 puts sized to 1–3% portfolio notional, paired with long $15 puts to cap downside (sell $20 / buy $15 put spread), target net credit ≈$4–$5 for ~20–30% return on margin; set stop-loss if IMNM < $14.50 (assignment threshold). Alternative: buy‑write at $20.16 and sell $22 Jan‑2028 calls for ~41% gross return if called, but size small (1–2% equity) to avoid missing upside; avoid naked long volatility given rich IV — prefer selling calendar or wheel strategies.

Contrarian angles: Consensus underweights company‑specific funding risk and overweights premium-selling safety — implied>real vol only ~6pp, not massive, so selling is NOT free money against a binary biotech. Historical parallels: post‑secondary small‑cap biotechs often mean‑revert 30–60% over 6–12 months absent positive readouts — if IMNM prints neutral/negative data, expect a fast unwind. Unintended consequence: heavy put selling may concentrate assigned shares at ~$14.50 basis creating a crowded long base that amplifies downside on bad news.

Key Decisions for Investors

• Establish a defined‑risk short premium trade: sell IMNM Jan‑2028 $20 put and buy Jan‑2028 $15 put (5‑point width) sized to 1–3% portfolio notional; target net credit ≈ $4.00–$5.50, max loss = $5.00 – credit, and close/roll if IMNM < $14.50 or if IV rallies >20 vols.
• Consider a buy‑write: purchase IMNM shares up to 1–2% portfolio weight at market ($20.16) and sell Jan‑2028 $22 calls for $6.50 to lock a 41% gross return if called; cap position and predefine re‑entry if price > $30 or expiration approaches with >20% intrinsic upside left.
• Avoid buying naked long calls/straddles given 84–85% IV; instead, if directional bullish on near‑term data, use debit spreads (buy $20/$25 call spread) to limit gamma decay and cap cost — deploy within 30–90 days of a known catalyst.
• Monitor three concrete catalysts over the next 30–90 days before increasing size: (1) upcoming trial readout dates, (2) cash runway disclosure <12 months, (3) any announced secondary offering; reduce exposure by 50% if any of these triggers occur.